Akeega Plus Prednisone Approved for BRCA-mutated mCRPC

The FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), ...

AUGUST 14, 2023

Continuing Enzalutamide After Progression and Adding Docetaxel Improved PFS in mCRPC, Study Shows

Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended ...

MARCH 25, 2022

Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer

The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for ...

MARCH 25, 2022

PROfound Trial: OS Improvement With Olaparib in Subset of Patients With mCRPC

In men with metastatic castration-resistant prostate cancer and mutations in genes associated with homologous ...

MARCH 3, 2021

Lynparza Approved for Use in HRR-Mutated mCRPC

The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...

MAY 28, 2020

Rubraca Gains Approval for Use in BRCA-Mutated mCRPC

The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...

MAY 19, 2020

Two Trials Clarify Role of Cabazitaxel in mCRPC

Chicago—Two Phase III trials elucidate the role of cabazitaxel in the treatment of metastatic ...

AUGUST 10, 2016